These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35961884)

  • 1. Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors.
    Suzuki Y; Kaneko H; Okada A; Matsuoka S; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Node K; Nangaku M; Yasunaga H; Komuro I
    Kidney Int; 2022 Nov; 102(5):1147-1153. PubMed ID: 35961884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
    Suzuki Y; Kaneko H; Okada A; Itoh H; Matsuoka S; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Kamiya K; Matsunaga A; Ako J; Node K; Yasunaga H; Komuro I
    Cardiovasc Diabetol; 2022 May; 21(1):67. PubMed ID: 35585590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight change associated kidney outcomes of sodium-glucose cotransporter new users.
    Jimba T; Kaneko H; Azegami T; Suzuki Y; Okada A; Ko T; Fujiu K; Takeda N; Morita H; Hayashi K; Nishiyama A; Node K; Yasunaga H; Takeda N; Nangaku M; Komuro I
    Diabetes Obes Metab; 2024 Oct; 26(10):4535-4543. PubMed ID: 39072974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
    Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL
    Cardiovasc Diabetol; 2022 Sep; 21(1):194. PubMed ID: 36151557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
    Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
    Nakhleh A; Abdul-Ghani M; Gazit S; Gross A; Livnat I; Greenbloom M; Yarden A; Khazim K; Shehadeh N; Melzer Cohen C
    Diabetes Obes Metab; 2024 Aug; 26(8):3058-3067. PubMed ID: 38680053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
    Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus.
    Bhosle D; Indurkar S; Quadri U; Chandekar B
    J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
    Kang A; Smyth B; Neuen BL; Heerspink HJL; Di Tanna GL; Zhang H; Arnott C; Hockham C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Mahaffey KW; Perkovic V; Jardine MJ
    Diabetes Obes Metab; 2023 Aug; 25(8):2151-2162. PubMed ID: 37161691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
    Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of risk factors associated with acute kidney injury in patients taking sodium-glucose cotransporter-2 inhibitors.
    Schumacher C; Chorpash A; Bolch C; Eagan K; Nimer S; Van Dril E
    Pharmacotherapy; 2024 Mar; 44(3):249-257. PubMed ID: 38131129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.